Australia's most trusted
source of pharma news
Posted 9 December 2025 AM
CSL has got some new ammunition to support a premium price for its gene therapy when it negotiates with the government over funding.
MSAC supported public funding for haemophilia b gene therapy Hemgenix under the National Blood Agreement last month, but at a lower price than sought by CSL. Hemgenix is the world's second most expensive drug, sold overseas for around $5.3 million, but the Committee said the four-year follow-up data did not support the durability of the treatment over a lifetime.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.